Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||JPRN-UMIN000012489||2013/12/04||04/12/2013||Efficacy of anti-RANKL human antibody (Denosumab) on prevention of osteoporosis with primary biliary cirrhosis||Osteoporosis in biopsy-proven PBC who was not pretreated with denosumab and/or bisphosphonate in recent 6 months||For osteoporosis patients who need treatment based on PBC treatment guideline, 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately. PBC patients who do not meet osteoporosis treatment criteria will be followed.||Juntendo University School of Medicine||NULL||Complete: follow-up continuing||20years-old||Not applicable||Male and Female||20||Not applicable||Japan|
|2||JPRN-UMIN000012193||2013/11/01||01/11/2013||Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis||Osteoporosis in biopsy-proven primary biliary cirrhosis patients pretreated with bisphosphonate||Discontinue the administration of aredoron acid, risedronic acid, and minodronic acid. Then, 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately.|
Continue the administration of bisphosphonate as heretofore. All patients will take activated vitamin D.
|Juntendo University School of Medicine||NULL||Complete: follow-up complete||20years-old||Not applicable||Male and Female||60||Not applicable||Japan|